Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04932837

Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences

Determination of the Level of Immunity, Neutralization of the SARS-COV-2 Virus and Reinfections in Residents of 2 Migrant Workers' Residences 10 Months Apart

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Epicentre · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

A previous seroprevalence survey showed very high seroprevalence levels among residents of the two among the residents of the two migrant workers' hostels surveyed, indicating a high level of circulation of the virus SARS-COV-2 during the 1st wave of COVID-19. The constitution of a cohort after the event would be an opportunity to obtain opportunity to obtain answers to crucial questions: duration of immunity, potential reinfections potential reinfections, potential re-clustering. Going back to check the serological status seems feasible, especiallyespecially in the Foyers de Travailleurs Migrants (high probability of finding the participants). There is an obvious scientific interest around the duration of immunity and reinfections in a population highly exposed during the first wave. Several articles document the decline of IgG antibodies in the months following an infection, but very few infection, but very few evaluate the protective character in the medium term (\>=6 months), especially in asymptomatic individuals. We are also concerned about the circulation of We are also concerned about the circulation of new variants and the immunity acquired after infection in residents. To date, no study on the duration of immunity has been conducted in migrant worker's residences.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood and Saliva collectionSerological, viral RNA and antigenic test

Timeline

Start date
2021-06-14
Primary completion
2021-06-25
Completion
2021-07-02
First posted
2021-06-21
Last updated
2021-06-21

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04932837. Inclusion in this directory is not an endorsement.